scispace - formally typeset
S

Sonia Lozano

Researcher at GlaxoSmithKline

Publications -  14
Citations -  790

Sonia Lozano is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Plasmodium falciparum & Gametocyte. The author has an hindex of 9, co-authored 14 publications receiving 688 citations. Previous affiliations of Sonia Lozano include University of Wisconsin–Superior.

Papers
More filters
Journal ArticleDOI

Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis.

TL;DR: With the aim of fuelling open‐source, translational, early‐stage drug discovery activities, the results of the recently completed antimycobacterial phenotypic screening campaign against Mycobacterium bovis BCG with hit confirmation in M. tuberculosis H37Rv were made publicly accessible.
Journal ArticleDOI

Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence “transmission blocking”assay

TL;DR: An efficient method to produce and purify mature gametocytes in vitro and an assay to determine the activity of antimalarial drugs based on the intracellular ATP content of purified stage IV–Vgametocytes after 48 h of drug exposure in 96/384-well microplates are designed.
Book ChapterDOI

Evaluation of a Bacterial Bioluminescence Bioassay as a Method for Predicting Acute Toxicity of Organic Chemicals to Fish

TL;DR: The relationship between the toxicity of 68 organic chemicals to fish and luminescent bacteria was evaluated in this article, where the feasibility of using the bacterial bioassay as a screening test in a cost-effective testing scheme was discussed.
Journal ArticleDOI

A New Set of Chemical Starting Points with Plasmodium falciparum Transmission-Blocking Potential for Antimalarial Drug Discovery.

TL;DR: Screening results for the Tres Cantos Antimalarial Set (TCAMS) report the identification of 98 selective molecules with dual activity against gametocytes and asexual stages, and new chemical structures not connected to previously described antimalarials have been identified.
Journal ArticleDOI

Antifungal Activities and Cytotoxicity Studies of Six New Azasordarins

TL;DR: In vitro selectivity of azasordarins showed significant activity against emerging fungal pathogens, which affect immunocompromised patients, such as Rhizopus arrhizus, Blastoschizomyces capitatus, and Geotrichum clavatum.